<?xml version='1.0' encoding='utf-8'?>
<document id="29464465"><sentence text="The concomitant use of lapatinib and paracetamol - the risk of interaction."><entity charOffset="23-32" id="DDI-PubMed.29464465.s1.e0" text="lapatinib" /><entity charOffset="37-48" id="DDI-PubMed.29464465.s1.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.29464465.s1.e0" e2="DDI-PubMed.29464465.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s1.e0" e2="DDI-PubMed.29464465.s1.e1" /></sentence><sentence text="Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer"><entity charOffset="0-9" id="DDI-PubMed.29464465.s2.e0" text="Lapatinib" /><entity charOffset="15-23" id="DDI-PubMed.29464465.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.29464465.s2.e0" e2="DDI-PubMed.29464465.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s2.e0" e2="DDI-PubMed.29464465.s2.e1" /></sentence><sentence text=" Paracetamol is an analgesic commonly applied to patients with mild or moderate pain and fever"><entity charOffset="1-12" id="DDI-PubMed.29464465.s3.e0" text="Paracetamol" /></sentence><sentence text=" Cancer patients are polymedicated, which involves high risk of drug interactions during therapy" /><sentence text=" The aim of the study was to assess the interaction between lapatinib and paracetamol in rats"><entity charOffset="60-69" id="DDI-PubMed.29464465.s5.e0" text="lapatinib" /><entity charOffset="74-85" id="DDI-PubMed.29464465.s5.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.29464465.s5.e0" e2="DDI-PubMed.29464465.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s5.e0" e2="DDI-PubMed.29464465.s5.e1" /></sentence><sentence text=" The rats were divided into three groups of eight animals in each" /><sentence text=" One group received lapatinib + paracetamol (IL + PA), another group received lapatinib (IIL), whereas the last group received paracetamol (IIIPA)"><entity charOffset="20-43" id="DDI-PubMed.29464465.s7.e0" text="lapatinib + paracetamol" /><entity charOffset="45-52" id="DDI-PubMed.29464465.s7.e1" text="IL + PA" /><entity charOffset="78-87" id="DDI-PubMed.29464465.s7.e2" text="lapatinib" /><entity charOffset="127-138" id="DDI-PubMed.29464465.s7.e3" text="paracetamol" /><entity charOffset="140-145" id="DDI-PubMed.29464465.s7.e4" text="IIIPA" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e0" e2="DDI-PubMed.29464465.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e0" e2="DDI-PubMed.29464465.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e0" e2="DDI-PubMed.29464465.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e0" e2="DDI-PubMed.29464465.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e0" e2="DDI-PubMed.29464465.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e1" e2="DDI-PubMed.29464465.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e1" e2="DDI-PubMed.29464465.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e1" e2="DDI-PubMed.29464465.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e1" e2="DDI-PubMed.29464465.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e2" e2="DDI-PubMed.29464465.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e2" e2="DDI-PubMed.29464465.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e2" e2="DDI-PubMed.29464465.s7.e4" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e3" e2="DDI-PubMed.29464465.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29464465.s7.e3" e2="DDI-PubMed.29464465.s7.e4" /></sentence><sentence text=" A single dose of lapatinib (100 mg/kg b"><entity charOffset="18-27" id="DDI-PubMed.29464465.s8.e0" text="lapatinib" /></sentence><sentence text="w" /><sentence text=") and paracetamol (100 mg/kg b"><entity charOffset="6-17" id="DDI-PubMed.29464465.s10.e0" text="paracetamol" /></sentence><sentence text="w" /><sentence text=") was administered orally" /><sentence text=" Plasma concentrations of lapatinib, paracetamol and its metabolites - glucuronide and sulphate, were measured with the validated HPLC-MS/MS method and HPLC-UV method, respectively"><entity charOffset="26-35" id="DDI-PubMed.29464465.s13.e0" text="lapatinib" /><entity charOffset="37-48" id="DDI-PubMed.29464465.s13.e1" text="paracetamol" /><entity charOffset="87-95" id="DDI-PubMed.29464465.s13.e2" text="sulphate" /><pair ddi="false" e1="DDI-PubMed.29464465.s13.e0" e2="DDI-PubMed.29464465.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s13.e0" e2="DDI-PubMed.29464465.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s13.e0" e2="DDI-PubMed.29464465.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s13.e1" e2="DDI-PubMed.29464465.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s13.e1" e2="DDI-PubMed.29464465.s13.e2" /></sentence><sentence text=" The pharmacokinetic parameters of both drugs were calculated using non-compartmental methods" /><sentence text=" The co-administration of lapatinib and paracetamol increased the area under the plasma concentration-time curve (AUC) and the maximum concentration (Cmax) of lapatinib by 239"><entity charOffset="26-35" id="DDI-PubMed.29464465.s15.e0" text="lapatinib" /><entity charOffset="40-51" id="DDI-PubMed.29464465.s15.e1" text="paracetamol" /><entity charOffset="159-168" id="DDI-PubMed.29464465.s15.e2" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.29464465.s15.e0" e2="DDI-PubMed.29464465.s15.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s15.e0" e2="DDI-PubMed.29464465.s15.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s15.e0" e2="DDI-PubMed.29464465.s15.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s15.e1" e2="DDI-PubMed.29464465.s15.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s15.e1" e2="DDI-PubMed.29464465.s15.e2" /></sentence><sentence text="6% (p = 0" /><sentence text="0030) and 184% (p = 0" /><sentence text="0011), respectively" /><sentence text=" Lapatinib decreased the paracetamol AUC0-∞ by 48"><entity charOffset="1-10" id="DDI-PubMed.29464465.s19.e0" text="Lapatinib" /><entity charOffset="25-36" id="DDI-PubMed.29464465.s19.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.29464465.s19.e0" e2="DDI-PubMed.29464465.s19.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s19.e0" e2="DDI-PubMed.29464465.s19.e1" /></sentence><sentence text="8% and Cmax by 55" /><sentence text="7%" /><sentence text=" In the IL + PA group the Cmax of paracetamol glucuronide was reduced, whereas the Cmax of paracetamol sulphate was higher than in the IIIPA group"><entity charOffset="8-15" id="DDI-PubMed.29464465.s22.e0" text="IL + PA" /><entity charOffset="34-57" id="DDI-PubMed.29464465.s22.e1" text="paracetamol glucuronide" /><entity charOffset="91-111" id="DDI-PubMed.29464465.s22.e2" text="paracetamol sulphate" /><entity charOffset="135-140" id="DDI-PubMed.29464465.s22.e3" text="IIIPA" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e0" e2="DDI-PubMed.29464465.s22.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e0" e2="DDI-PubMed.29464465.s22.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e0" e2="DDI-PubMed.29464465.s22.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e0" e2="DDI-PubMed.29464465.s22.e3" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e1" e2="DDI-PubMed.29464465.s22.e1" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e1" e2="DDI-PubMed.29464465.s22.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e1" e2="DDI-PubMed.29464465.s22.e3" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e2" e2="DDI-PubMed.29464465.s22.e2" /><pair ddi="false" e1="DDI-PubMed.29464465.s22.e2" e2="DDI-PubMed.29464465.s22.e3" /></sentence><sentence text=" Paracetamol significantly affected the enhanced plasma exposure of lapatinib"><entity charOffset="1-12" id="DDI-PubMed.29464465.s23.e0" text="Paracetamol" /><entity charOffset="68-77" id="DDI-PubMed.29464465.s23.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.29464465.s23.e0" e2="DDI-PubMed.29464465.s23.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s23.e0" e2="DDI-PubMed.29464465.s23.e1" /></sentence><sentence text=" Additionally, lapatinib reduced the concentrations of paracetamol"><entity charOffset="15-24" id="DDI-PubMed.29464465.s24.e0" text="lapatinib" /><entity charOffset="55-66" id="DDI-PubMed.29464465.s24.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.29464465.s24.e0" e2="DDI-PubMed.29464465.s24.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s24.e0" e2="DDI-PubMed.29464465.s24.e1" /></sentence><sentence text=" The co-administration of lapatinib decreased the paracetamol glucuronidation but increased the sulphation"><entity charOffset="26-35" id="DDI-PubMed.29464465.s25.e0" text="lapatinib" /><entity charOffset="50-61" id="DDI-PubMed.29464465.s25.e1" text="paracetamol" /><pair ddi="false" e1="DDI-PubMed.29464465.s25.e0" e2="DDI-PubMed.29464465.s25.e0" /><pair ddi="false" e1="DDI-PubMed.29464465.s25.e0" e2="DDI-PubMed.29464465.s25.e1" /></sentence><sentence text=" The findings of this study may be of clinical relevance to patients requiring analgesic therapy" /><sentence text="" /></document>